Pacific Biosciences
PACB
119 hedge funds and large institutions have $686M invested in Pacific Biosciences in 2015 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 36 increasing their positions, 29 reducing their positions, and 12 closing their positions.
340% more capital invested
Capital invested by funds: $156M → $686M (+$530M)
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
242% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 12
32% more funds holding
Funds holding: 90 → 119 (+29)
24% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 29
9% less call options, than puts
Call options by funds: $8.36M | Put options by funds: $9.18M
Top Buyers
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$32.5M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$29.5M |
| 3 |
BM
Bridger Management
New York
|
+$19.4M |
| 4 |
Renaissance Technologies
New York
|
+$14.2M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$6.91M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$21.8M |
| 2 |
DM
Deerfield Management
New York
|
-$7.16M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$6.81M |
| 4 |
RCM
Raging Capital Management
Rocky Hill,
New Jersey
|
-$5.73M |
| 5 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
-$2.93M |
PACB Hedge Fund Activity: Q4 2015 in Review
119 of the 3,811 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2015, worth a combined $686M — up 340% from $156M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new PACB positions and 12 closed out — a net gain of 29 holders — while 36 added to existing stakes and 29 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $32.5M. The largest seller was Millennium Management, cutting an estimated $21.8M.
- 119 institutional investors held Pacific Biosciences (PACB) as of Q4 2015, up from 90 in Q3 2015.
- Funds reported $686M of Pacific Biosciences stock for Q4 2015, up 340% quarter-over-quarter.
- 41 funds opened new Pacific Biosciences positions in Q4 2015 and 12 closed out, a net change of +29 holders.
- The largest Pacific Biosciences buyer in Q4 2015 was Lord, Abbett & Co, an estimated $32.5M added.
- The largest Pacific Biosciences seller in Q4 2015 was Millennium Management, an estimated $21.8M sold.
Based on aggregated 13F filings for Q4 2015.